<DOC>
	<DOCNO>NCT03061058</DOCNO>
	<brief_summary>Tumor messenger ribonucleic acid ( mRNA ) expression level may promise role potential predictive biomarkers chemotherapy . Peritoneal carcinomatosis appear common pattern metastasis recurrence associate poor prognosis gastric cancer patient . Intraperitoneal chemotherapy widely accept strategy treatment peritoneal dissemination . In study , aim evaluate impact individualize selection chemotherapeutics intraperitoneal combined system chemotherapy overall survival , disease free survival , response rate , safety advance gastric cancer patient .</brief_summary>
	<brief_title>Individualized Intraperitoneal System Chemotherapy Versus System Chemotherapy First-line Chemotherapy AGC</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Patients must histologically confirm adenocarcinoma stomach gastrooesophageal junction inoperable locally advanced metastatic disease , amenable curative therapy . Patients must measurable disease , accord Response Evaluation Criteria Solid Tumors ( RECIST , v1.1 ) , assess use image technique ( CT MRI ) . Patients must enough tumor tissue mRNA expression test . Women childbearing potential must nonpregnant ( negative pregnancy test within 72 hour prior chemotherapy , postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential ) nonlactating , men woman must willing exercise effective form birth control ( abstinence/contraception ) study 6 month therapy complete Eastern Cooperative Oncology Group ( ECOG ) Performance status 0 , 1 2 . Absolute neutrophil count ( ANC ) &gt; =1,500/ul Platelets ( PLT ) &gt; =75,000/ul Serum bilirubin &lt; = 1.5 × upper limit normal ( ULN ) Aspartate transaminase ( AST ) alanine aminotransferase ( ALT ) &lt; = 2.5 × ULN ( &lt; = 5 × ULN patient liver metastasis ) Alkaline phosphatase &lt; = 2.5 × ULN ( &lt; = 5 × ULN patient liver metastasis , &lt; = 10 × ULN patient bone liver metastasis ) Albumin &gt; = 25 g/L . Creatinine clearance &gt; = 60 mL/min . Life expectancy least 3 month . Signed informed consent . Previous chemotherapy advanced/metastatic disease ( prior adjuvant/neoadjuvant therapy allow least 6 month elapse completion adjuvant/neoadjuvant therapy enrolment study ; total dose cisplatin le 300mg/m^2 ) . Patients active ( significant uncontrolled ) gastrointestinal bleeding . Residual relevant toxicity result previous therapy ( exception alopecia ) , e.g . neurological toxicity ≥ grade 2 NCICTCAE 4.0 . Other malignancy within last 5 year , except carcinoma situ cervix , basal cell carcinoma . History document congestive heart failure ; angina pectoris require medication ; evidence transmural myocardial infarction ECG ; poorly control hypertension ( systolic BP &gt; 180 mmHg diastolic BP &gt; 100 mmHg ) ; clinically significant valvular heart disease ; high risk uncontrollable arrhythmia . Baseline leave ventricular ejection fraction ( LVEF ) &lt; 50 % ( measure echocardiography MUGA ) . Patients dyspnoea rest due complication advance malignancy disease , require supportive oxygen therapy . Patients receive chronic high dose corticosteroid therapy . ( Inhaled steroid short course oral steroid antiemesis appetite stimulant allow ) . Clinically significant hearing abnormality . Known dihydropyrimidine dehydrogenase ( DPD ) deficiency . History clinical evidence brain metastasis . Serious uncontrolled systemic intercurrent illness , e.g . infection poorly control diabetes . Positive serum pregnancy test woman childbearing potential . Received investigational drug treatment within 4 week start study treatment . Radiotherapy within 4 week start study treatment ( 2 week interval allow palliative radiotherapy give bone metastatic site peripherally patient recover acute toxicity ; prior adjuvant radiotherapy allow complete least 6 month ) . Major surgery within 4 week start study treatment , without complete recovery . Patients know active infection HIV , hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) . Known hypersensitivity study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>